Medical Doctor Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

Michael Langan

Internal Medicine Westerville, OH Medical Doctor

NPI 1770618688 CMS profile 812300

625 Africa Rd Ste 200, Westerville, OH 43082

Open in the dashboard

General payments

$14,348

869 records reported · program years 2020–2025

Research payments

$0

Paid to them · None reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Michael Langan of Westerville, OH is reported in the CMS Open Payments database as having received $14,348 across 869 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,580 138
2024 General $3,272 171
2023 General $2,961 173
2022 General $2,470 164
2021 General $2,375 175
2020 General $690 48

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michael Langan
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Michael Langan were reported at $2,580. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Michael Langan Internal Medicine median Middle half National median
2019 $0 $159 $48–$570 $163
2020 $690 $119 $33–$402 $114
2021 $2,375 $135 $37–$521 $132
2022 $2,470 $141 $42–$496 $149
2023 $2,961 $149 $45–$519 $160
2024 $3,272 $154 $47–$537 $164
2025 $2,580 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. Novo Nordisk Inc $1,991 138 payments
  2. AbbVie, Inc. $1,698 128 payments
  3. Lilly USA, LLC $1,134 65 payments
  4. Amgen Inc. $837 52 payments
  5. Pfizer Inc. $810 49 payments
  6. Xeris Pharmaceuticals, Inc. $652 36 payments
  7. Janssen Pharmaceuticals, Inc $571 37 payments
  8. AstraZeneca Pharmaceuticals LP $570 28 payments
  9. Boehringer Ingelheim Pharmaceuticals, Inc. $535 34 payments
  10. Novartis Pharmaceuticals Corporation $479 29 payments
  11. Other $5,070 273 payments

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Food and Beverage $14,334 868 payments
  2. Education $14 1 payment
Products named General payments · program years 2020–2025
  1. Ozempic $1,420 98 payments
  2. RYBELSUS $1,381 95 payments
  3. UBRELVY $863 62 payments
  4. XARELTO $571 37 payments
  5. MOUNJARO $568 29 payments
  6. EVENITY $495 31 payments
  7. JARDIANCE $433 26 payments
  8. QULIPTA $429 35 payments
  9. Prolia $409 26 payments
  10. VRAYLAR $377 24 payments
  11. Other $12,410 718 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 143 drugs

Part D claims

8,270

Median for Internal Medicine: 777

Drug cost

$735,730

Median for Internal Medicine: $73,373

Branded share of claims

23%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 86 $119,569
Eliquis Apixaban Brand 87 $109,203
Xarelto Rivaroxaban Brand 56 $57,486
Jardiance Empagliflozin Brand 40 $55,342
Farxiga Dapagliflozin Propanediol Brand 58 $55,207
Tresiba Flextouch U-200 Insulin Degludec Brand 19 $35,648
Rybelsus Semaglutide Brand 15 $29,470
Trulicity Dulaglutide Brand 16 $24,089
Mounjaro Tirzepatide Brand 20 $20,654
Humulin R U-500 Kwikpen Insulin Regular, Human Brand 17 $18,430

The 10 drugs with the highest cost, of 143 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 162 billing codes

Paid by Medicare

$182,098

Of which drugs: $30,162

Medicare patients

357

Average age 75

Services billed

11,218

156 women, 201 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 73%
Arthritis 45%
Diabetes 27%
Ischemic heart disease 25%
Chronic kidney disease 25%
Depression 21%
Osteoporosis 18%
Atrial fibrillation 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Sarscov2 vac 50 mcg/0.5ml im 91322 Office 71 74 $11,553
Vaccine for influenza for injection into muscle 90662 Office 136 136 $11,088
Pcv20 vaccine im 90677 Office 23 23 $6,699

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 48 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
MOUNJARO
$197 20 —
AIRSUPRA
$179 — —
LEQVIO
$162 — —
JARDIANCE
$155 40 —
VRAYLAR
$119 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 48 with Patron

Records

869 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record